ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / BMRN / forecast
ELAN (45) RDY (64) SYRE (55) SMMT (40) ⌘ Pro Terminal →

BioMarin Pharmaceutical Inc. (BMRN) 12-Month Stock Forecast & Price Target Cone

$58.51 +1.77% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $58.84

BioMarin Pharmaceutical Inc. (BMRN) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (78% profit margin, 6% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate) →
ROARABLE B • BUY Cap $11.33B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BMRN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BMRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $58.51 (+1.77% 1D, market cap $11.33B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, BMRN ranks #38 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BMRN compare to ELAN and RDY in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BMRN carries a Roarable B (74/100 RQD), trailing P/E of 31.9x, gross margin of 77.7%, and ROIC of 6.0%. By comparison, ELAN (Elanco Animal Health Incorporated) holds a D grade (45/100 RQD, P/E N/A, ROIC -2.5%, cap $11.52B) and RDY (Dr. Reddy's Laboratories Ltd) posts a C grade (64/100 RQD, P/E 32.8x, ROIC 9.9%, cap $11.83B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BMRN?
▼

Per BMRN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001048477), BioMarin Pharmaceutical Inc. generated $3.22B in revenue (+12.9% YoY), $348.9M in net income, and $725.0M in free cash flow against $7.59B in total assets and $597.2M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $58.84 (+0.56%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 22.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510074
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk A-
Cash (14)Whales (11)SEC (18)Macro (16)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+7.2% Base Target
$75 Bull$63 Base$48 Bear
📬 FREE BMRN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BMRN)Realized 20D OHLCV Swing Band: ±5.7%
Deterministic 5-Pillar Attribution (74/100 Composite)
🔍 WHY BMRN SCORES 74/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (24% of score)

Altman Z-Score 5.57 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Macro Regime Fit+16/20 pts (22% of score)

FRED Regime × Technicals: 43% of 52W Range • RSI-14 at 54.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
66
Grade B-$55.14+0.1% Next Q
Q2 (-2Q)
69
Grade B-$55.21+1.4% Next Q
Q3 (-1Q)
71
Grade B$56.00+4.5% Next Q
Current
74
Grade B$58.51+7.3% Hist 90D α
Trajectory: B- (66) → B (74)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the BMRN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 74/100 (B) score, BMRN faces multiple-compression risk if 31.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 75.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($60.13) or 200D SMA ($58.47) invalidates the momentum regime and cuts Target Base ($62.72) toward Bear Floor ($47.98).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BMRN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BMRN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 74%NO 26%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your BMRN Position Size: $10,000

Shares at $58.51: 170.9 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $47.98
$8,200
$-1,800 (-18.0%)
12M Consensus BaseTarget $62.72
$10,720
+$720 (+7.2%)
12M Bull Case BreakoutTarget $74.53
$12,738
+$2,738 (+27.4%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (34 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 23● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskOUTPERFORM$6574%A
Goldman SachsSector Coverage LeadSTRONG BUY$7069%B
JP MorganUS Large-Cap ResearchHOLD$5558%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (BMRN Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BMRN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +5.50%📐 HORIZONTAL RANGE
2026-11-03O $57.49H $58.51L $57.49C $58.51VOL 2.27M
RES: $74.58SUP: $51.75SMA50: $60.13SMA200: $58.47
$72.50$66.20$59.90$53.60$47.31RES $74.58SUP $51.75$58.512026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BMRN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BMRN Butterfly Map → + Track BMRN →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
24.6%/yr Implied 5Y Growth

vs. +12.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BMRN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BMRN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BMRN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BMRN)

Health Care Rank #38 of 1016 ⚔️ ELAN vs BMRN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BMRN vs. ELAN, RDY, SYRE, SMMT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BioMarin Pharmaceutical Inc. (BMRN) ranks #38 by composite RQD confidence (74/100, grade B) and #97 by equity capitalization ($11.33B). Within this direct 5-issuer industry benchmark cohort, BMRN leads on earnings valuation at 31.9x trailing P/E, while RDY leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. BMRN currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BMRN ACTIVE
BioMarin Pharmaceutical Inc.
B 74/100 31.9x 77.7% 6.0% +1.77% $11.33B Benchmark Subject
ELAN
Elanco Animal Health Incorporated
D 45/100 — 55.0% -2.5% -0.77% $11.52B /elan-vs-bmrn →
RDY
Dr. Reddy's Laboratories Ltd
C 64/100 32.8x — 9.9% +0.43% $11.83B /rdy-vs-bmrn →
SYRE
Spyre Therapeutics Inc.
D+ 55/100 — — -20.0% -2.42% $10.08B /syre-vs-bmrn →
SMMT
Summit Therapeutics Inc.
D- 40/100 — — -35.0% -1.05% $12.82B /smmt-vs-bmrn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001048477

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioMarin Pharmaceutical Inc. (BMRN) reported GAAP revenue of $3.22B (+12.9% vs. FY2024 revenue of $2.85B , and +33.2% cumulative change since FY2023) , GAAP net income of $348.9M, operating cash flow of $828.0M, and free cash flow of $725.0M (+48.7% YoY). On the balance sheet, BMRN closed FY2025 with $7.59B in total assets against $597.2M in total debt (Altman Z-Score: 5.57, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.22B $348.9M $828.0M $725.0M $7.59B $597.2M
FY2024 (FY) 2024-12-31 $2.85B $426.9M $572.8M $487.4M $6.99B $598.9M
FY2023 (FY) 2023-12-31 $2.42B $167.6M $159.3M $50.4M $6.12B $1.43B

3. BMRN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BMRN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $58.51 (+1.77% 1D, market cap $11.33B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, BMRN ranks #38 in composite RQD confidence.

How does BMRN compare to ELAN and RDY in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BMRN carries a Roarable B (74/100 RQD), trailing P/E of 31.9x, gross margin of 77.7%, and ROIC of 6.0%. By comparison, ELAN (Elanco Animal Health Incorporated) holds a D grade (45/100 RQD, P/E N/A, ROIC -2.5%, cap $11.52B) and RDY (Dr. Reddy's Laboratories Ltd) posts a C grade (64/100 RQD, P/E 32.8x, ROIC 9.9%, cap $11.83B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BMRN?

Per BMRN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001048477), BioMarin Pharmaceutical Inc. generated $3.22B in revenue (+12.9% YoY), $348.9M in net income, and $725.0M in free cash flow against $7.59B in total assets and $597.2M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BMRN trading relative to its 50-day, 200-day, and 52-week technical levels?

BMRN last traded at $58.51 (+1.77% on volume of 2,274,071 shares), positioning the stock -2.69% below its 50-day simple moving average ($60.13) and +0.07% above its 200-day simple moving average ($58.47). Across its 52-week range of $49.26 to $70.98, BMRN sits at the 42.6% percentile with a 14-day RSI of 54.4 (NEUTRAL RANGE) and an implied next-earnings move of ±5.7% ($55.17 to $61.85).

BMRN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is BMRN's 12-month stock price target?

BioMarin Pharmaceutical Inc. (BMRN) carries a 12-month consensus base price target of $62.72 (+7.2% from $58.51), with a bull-case target of $74.53 and a bear-case floor of $47.98.

Is BMRN stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates BMRN B (Buy — BUY) with an RQD Confidence score of 74/100.

Direct Sub-Reports: BMRN RQD Cockpit BMRN 12M Forecast BMRN Earnings & Move BMRN Dividends & DRIP BMRN Insiders & 13F BMRN Whale Options BMRN Profit Sankey BMRN News & Why
ROARABLE RATING BRIEF • RQD 74/100 (B) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BMRN — BioMarin Pharmaceutical Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:16:03Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BMRN scores 67 out of 100 with a letter grade of C+ and a verdict of "Roarable Hold — Upper Neutral / Watch for Breakout." The five pillars are:

  • Fundamental Cash Engine: 14 / 20. The rating cites ROIC of 6% and an FCF yield of 6.51%. These are moderate readings: the business generates cash, but returns on capital are not strong relative to the valuation multiples shown in the market data.
  • Whale 13F Flow: 9 / 20. The rating describes institutional accumulation and options positioning as a weak pillar. No underlying 13F holdings data is supplied in the source, so the score cannot be traced to specific filings.
  • Insider Conviction: 15 / 20. The rating references SEC Form 4 and Congressional PTR cluster flow. The supporting trade-level detail is not included in the source data.
  • Macro Regime Fit: 11 / 20. The rating cites a beta of 0.95 and sector sensitivity. A beta near 1 means the stock has roughly market-level sensitivity to broad moves.
  • Forensic Balance Sheet: 18 / 20. This is the strongest pillar. The rating cites an Altman Z-Score of 5.57, a Piotroski F-Score of 8/9, and Debt/Equity of 0.1.

Investor implications, framed analytically: the upside drivers visible in the data are the strong balance sheet and positive free cash flow. The valuation tradeoff is that the stock trades at a P/E (TTM) of 31.9 and an EV/EBITDA of 21, with a forward P/E of 26.8, while ROIC sits at 6%. The "Watch for Breakout" label implies the rating is waiting on confirmation from the weaker pillars (institutional flow and macro fit) rather than signaling conviction in either direction.

Snapshot

MetricValue
Price57.49
Market Cap$11.13B
P/E (TTM)31.9
Forward P/E26.8
EV/EBITDA21
EPS (TTM)1.8
Dividend Yield0%
Beta0.95
52-Wk Range$49.26 - $70.98
ROIC %6%

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$3221.3M$409.5M$348.9MN/A$725.0M$1311.7M$597.2M
FY 2024$2853.9M$484.2M$426.9MN/A$487.4M$942.8M$598.9M
FY 2023$2419.2M$185.8M$167.6MN/A$50.4MN/A$1432.2M

Per the SEC financials, revenue grew from $2419.2M (FY 2023) to $3221.3M (FY 2025). Net income was $348.9M in FY 2025, down from $426.9M in FY 2024. Market data shows a gross margin of 77.7%, operating margin of 12.7%, and net margin of 10.8%. ROIC is 6%. Per the RQD forensic pillar, the Altman Z-Score is 5.57 and the Piotroski F-Score is 8/9. Debt/Equity is 0.1, and cash of $1311.7M in FY 2025 exceeds debt of $597.2M.

Open Questions

  • What specific catalyst drove the price change of 2.66% and the volume of 2,618,644 shown in market data?
  • Which products and revenue streams generate the FY 2025 revenue of $3221.3M?
  • What explains the drop in net income from $426.9M (FY 2024) to $348.9M (FY 2025) despite higher revenue?
  • What is the FY 2023 cash balance, which is recorded as N/A?
  • What institutional and insider flows underlie the Whale 13F and Insider Conviction pillar scores?

BMRN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BioMarin Pharmaceutical Inc. (BMRN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BMRN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BMRN Bull vs. Bear Conversation Board — What's Your Call at $58.51?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BMRN 🐻 50% BEARISH CONVICTION
1. Pick Your Side on BMRN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $62.09 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BMRN (C+ • RQD 67/100) a Buy at $57.49?

Welcome to the BMRN (BioMarin Pharmaceutical Inc.) Roar Pit. Current RQD Composite is 67/100 (Roarable Hold — Upper Neutral / Watch for Breakout) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (31.9x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $45.99 (-20.0%)
Spot @ $57.49

Pump the brakes on BMRN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BMRN, but look at what you are paying: 31.9x trailing P/E with 77.7% gross margins. Unless BioMarin Pharmaceutical Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $67.84 (+18.0%)
Spot @ $57.49

BMRN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BMRN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $57.49 (52-wk range $49.26 - $70.98), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%